Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03332238 · ClinicalTrials.gov registry record · Phase 2
Stromal Vascular Fraction Cell Therapy to Improve the Repair of Rotator Cuff Tears
A Phase 2 study of Rotator Cuff Tear and Muscle Atrophy, sponsored by Hospital for Special Surgery, New York.
- Active
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT03332238 is a Phase 2 study of Rotator Cuff Tear and Muscle Atrophy that is active but no longer recruiting, run by Hospital for Special Surgery, New York. The registered enrollment target is 56 participants, below the 89-participant average among 11 other Rotator Cuff Tear trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03332238, a Phase 2 study of Rotator Cuff Tear and Muscle Atrophy, is active but no longer recruiting, sponsored by Hospital for Special Surgery, New York.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
Rotator cuff disease is one of the most prevalent musculoskeletal conditions across the world. Patients with chronic rotator cuff tears often have substantial muscle atrophy and fatty infiltration. Surgical repair of the tear does not reverse the atrophy, and many patients continue to experience weakness, pain, and a persistent reduction in the quality of life. An important limitation in our ability to successfully rehabilitate these injuries postoperatively and return patients to normal function has to do with the poor quality of the muscle and tendon after rotator cuff repair. The stromal vascular fraction (SVF) of subcutaneous adipose tissue is highly enriched with cells (SVFCs) that can both directly participate in tissue regeneration by differentiating into myogenic and tenogenic cells, and indirectly by secreting growth factors and small molecules which activate pathways associated with healthy tissue regeneration. High numbers of autologous SVFCs can be isolated using the cost-effective, intraoperative Icellator (Tissue Genesis, Honolulu, HI) point-of-care system. This clinical trial will be determine if the use of SVFCs can enhance outcomes for patients who are undergoing surgical repair of a torn supraspinatus rotator cuff.
Conditions Studied
Interventions
- DEVICE Autologous Stomal Vascular Fraction Material
- DEVICE Ringer's solution
Study Locations (1)
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2026-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03332238
The ClinicalTrials.gov registry entry for NCT03332238 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 11 other Rotator Cuff Tear trials with a reported enrollment target (37% lower). The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Rotator Cuff Tear appearing as the primary indexed condition, and to 2 interventions - of which Autologous Stomal Vascular Fraction Material is the first listed.
NCT03332238 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03332238 about?
NCT03332238 is a clinical study titled "Stromal Vascular Fraction Cell Therapy to Improve the Repair of Rotator Cuff Tears". Rotator cuff disease is one of the most prevalent musculoskeletal conditions across the world. Patients with chronic rotator cuff tears often have substantial muscle atrophy and fatty infiltration. Surgical repair of the tear does not reverse the atrophy, and many patients continue to experience wea...
What is the current status of trial NCT03332238?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2019-07-01. Estimated completion is 2026-07-23.
What conditions does trial NCT03332238 study?
This clinical trial studies the following conditions: Rotator Cuff Tear, Muscle Atrophy, Tendon Tear.
What interventions are being tested in trial NCT03332238?
The interventions under investigation include: Autologous Stomal Vascular Fraction Material (DEVICE), Ringer's solution (DEVICE).
Who is sponsoring clinical trial NCT03332238?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03332238 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rotator Cuff Tear
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nonopioid Analgesia After Rotator Cuff Repair
COMPLETED · Phase 2
-
FiberLocker® System Augmentation of Rotator Cuff Repairs
RECRUITING · NA
-
Oxandrolone Rotator Cuff Trial
ACTIVE NOT RECRUITING · NA
-
Autologous Adult Adipose-Derived Regenerative Cell Injection Into Chronic Partial-Thickness Rotator Cuff Tears
ACTIVE NOT RECRUITING · NA
-
Rotator Cuff Failure With Continuity
ACTIVE NOT RECRUITING
-
Opioid-Free Shoulder Arthroplasty
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.